Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Maeda Website

Kenji Maeda, M.D., Ph.D.

Selected Publications

1)  Yedidi RS, Garimella H, Aoki M, Aoki H, Desai DV, Chang SB, Davis DA, Fyvie WS, Kaufman JD, Smith DW, Das D, Wingfield PT, Maeda K, Ghosh AK, Mitsuya H.
Conserved hydrogen-bonding network of P2 bis-tetrahydrofuran containing HIV-1 protease inhibitors (PI) with protease active site amino acid-backbone aid in their activity against PI-resistant HIV.
Antimicrob. Agents Chemother. 2014.
[Journal]
2)  Maeda K, Desai DV, Aoki M, Nakata H, Kodama EN, Mitsuya H.
Delayed emergence of HIV-1 variants resistant to 4'-ethynyl-2-fluoro-2'-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001.
Antivir Ther. 19: 179-89, 2013.
[Journal]
3)  Matsuzawa T, Kawamura T, Ogawa Y, Maeda K, Nakata H, Moriishi K, Koyanagi Y, Gatanaga H, Shimada S, Mitsuya H.
EFdA, a Reverse Transcriptase Inhibitor, Potently Blocks HIV-1 Ex Vivo Infection of Langerhans Cells within Epithelium.
J. Invest. Dermatol. 2013.
[Journal]
4)  Daniels SI, Soule EE, Davidoff KS, Bernbaum JG, Hu D, Maeda K, Stahl SJ, Naiman NE, Waheed AA, Freed EO, Wingfield P, Yarchoan R, Davis DA.
Activation of virus uptake through induction of macropinocytosis with a novel polymerizing peptide.
FASEB J. 2013.
[Journal]
5)  Yedidi RS, Maeda K, Fyvie WS, Steffey M, Davis DA, Palmer I, Aoki M, Kaufman JD, Stahl SJ, Garimella H, Das D, Wingfield PT, Ghosh AK, Mitsuya H.
P2' benzene carboxylic acid moiety is associated with decrease in cellular uptake: evaluation of novel nonpeptidic HIV-1 protease inhibitors containing P2 bis-tetrahydrofuran moiety.
Antimicrob. Agents Chemother. 57: 4920-7, 2013.
[Journal]
6)  Maeda K, Das D, Nakata H, Mitsuya H.
CCR5 inhibitors: emergence, success, and challenges.
Expert Opin Emerg Drugs. 17: 135-45, 2012.
[Journal]
7)  Maeda K, Das D, Mitsuya H.
Development of Antiviral Therapeutics for HIV-1 Infection and AIDS. In: HIV/AIDS in the Post-HAART Era: Manifestations, Treatment & Epidemiology.
USA: People's medical Publishing House - USA; 2011. p. 900-937 [Book Chapter]
8)  Maeda K, Das D, Yin PD, Tsuchiya K, Ogata-Aoki H, Nakata H, Norman RB, Hackney LA, Takaoka Y, Mitsuya H.
Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition.
J. Mol. Biol. 381: 956-74, 2008.
[Journal]
9)  Maeda K, Das D, Ogata-Aoki H, Nakata H, Miyakawa T, Tojo Y, Norman R, Takaoka Y, Ding J, Arnold GF, Arnold E, Mitsuya H.
Structural and molecular interactions of CCR5 inhibitors with CCR5.
J. Biol. Chem. 281: 12688-98, 2006.
[Journal]
10)  Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, Shibayama S, Sagawa K, Fukushima D, Moravek J, Koyanagi Y, Mitsuya H.
Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
J. Virol. 78: 8654-62, 2004.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 4/29/2014.